Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7

Diabetes Care

Volumn 36, Issue 4, 2013, Pages 908-913

  Hawa, Mohammed I ^a   Kolb, Hubert ^b   Schloot, Nanette ^b   Beyan, Huriya ^a   Paschou, Stavroula A ^a   Buzzetti, Raffaella ^c   Mauricio, Didac ^d   De Leiva, Alberto ^d   Yderstraede, Knud ^e   Beck Neilsen, Henning ^e   Tuomilehto, Jaakko ^f   Sarti, Cinzia ^f   Thivolet, Charles ^g   Hadden, David ^h   Hunter, Steven ^h   Schernthaner, Guntram ⁱ   Scherbaum, Werner A ^b   Williams, Rhys ^j   Brophy, Sinead ^j   Pozzilli, Paolo ^a,k   Leslie, Richard David ^a   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h ROYAL VICTORIA HOSPITAL   (United Kingdom)

ⁱ KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^j SWANSEA UNIVERSITY   (United Kingdom)

^k UNIVERSITY CAMPUS BIO MEDICO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; INSULINOMA ASSOCIATED ANTIGEN 2 ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 ANTIBODY;

ADULT; ADULT ONSET AUTOIMMUNE DIABETES MELLITUS; AGE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; EUROPE; FEMALE; HUMAN; INSULIN TREATMENT; LATENT AUTOIMMUNE DIABETES MELLITUS; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PREVALENCE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AUTOANTIBODIES; CATION TRANSPORT PROTEINS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE;

EID: 84875431011     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0931     Document Type: Article

References (21)

1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464:1293-1300
2. Leslie RD, Williams R, Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91:1654-1659
3. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150-157
4. Hosszúfalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003;26:452-457
5. Buzzetti R, Di Pietro S, Giaccari A, et al.; Non Insulin Requiring Autoimmune Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007;30:932-938
6. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes inNorthAmerica and Europe. Diabetes 2004;53:3193-3200
7. Turner R, Stratton I, Horton V, et al.; UK Prospective Diabetes Study Group. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997;350:1288-1293
8. Rosário PW, Reis JS, Amim R, et al. Comparison of clinical and laboratory characteristics between adult-onset type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 2005;28:1803-1804
9. Leslie RD, Kolb H, Schloot NC, et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24:511-519
10. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age?Diabetes 2005;54(Suppl. 2):S62-S67
11. Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005;48:2206-2212
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
13. Hawa MI, Fava D, Medici F, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 2000;23: 228-233
14. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007;104:17040-17045
15. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128-1136
16. Brophy S, Yderstraede K, Mauricio D, et al.; Action LADA Group. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008;31:439-441
17. Davies H, Brophy S, Fielding A, et al. Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterization. Diabet Med 2008;25:1354-1357
18. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001;44:3-15
19. Petrone A, Suraci C, Capizzi M, et al.; NIRAD Study Group. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3. Diabetes Care 2008;31: 534-538
20. Hawa MI, Thivolet C, Mauricio D, et al.; Action LADA Group. Metabolic syndrome and autoimmune diabetes: action LADAA 3. Diabetes Care 2009;32:160-164
21. Lorenzen T, Pociot F, Hougaard P, Nerup J. Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia 1994;37:321-327